Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Treatment sequence network meta-analysis in Crohn's disease: a methodological case study.

Abhishek Varu1, Florence R Wilson1, Peter Dyrda2

  • 1a Evidence Synthesis , Cornerstone Research Group , Burlington , Ontario , Canada.

Current Medical Research and Opinion
|February 8, 2019
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adjusted Comparison of First-line Enfortumab Vedotin Plus Pembrolizumab Versus Platinum-based Chemotherapy ± Avelumab Maintenance for the Treatment of Locally Advanced/Metastatic Urothelial Carcinoma.

European urology oncology·2026
Same author

Eating disorders: do rigid age limits for paediatrics serve our young people?

The New Zealand medical journal·2026
Same author

Comparative Effects of Individual Glucagon-Like Peptide-1 Receptor Agonist-Based Medications on Direct Measurement of Body Composition Among Adults With Overweight or Obesity With or Without Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials.

Diabetes, obesity & metabolism·2026
Same author

Analysing complex interventions using component network meta-analysis.

BMJ (Clinical research ed.)·2026
Same author

Updating the PRISMA reporting guideline for scoping reviews: a scoping review.

Journal of clinical epidemiology·2026
Same author

Author reply to Neilson et al: re Beyond beds and band-aids.

Internal medicine journal·2026

Ustekinumab shows the highest likelihood of achieving clinical response or remission in Crohn's disease patients after one year compared to placebo, adalimumab, and vedolizumab. This network meta-analysis provides valuable comparative efficacy data for biologic therapies.

Area of Science:

  • Gastroenterology
  • Immunology
  • Pharmacology

Background:

  • Biologic therapies are crucial for managing mild-to-moderate Crohn's disease (CD).
  • Assessing the comparative efficacy of different biologics is essential for treatment optimization.
  • Ustekinumab, adalimumab, vedolizumab, and infliximab are commonly used biologic agents.

Purpose of the Study:

  • To conduct a network meta-analysis (NMA) comparing the efficacy of ustekinumab, adalimumab, vedolizumab, and infliximab.
  • To evaluate the maintenance of clinical response and remission after one year of treatment in Crohn's disease patients.
  • To provide evidence-based insights into the comparative effectiveness of these biologic therapies.

Main Methods:

  • Systematic literature search to identify relevant randomized controlled trials (RCTs).
Keywords:
Crohn’s diseaseNetwork meta-analysisadaptive trial designbiologicsindirect treatment comparisonsstudy designustekinumab

Related Experiment Videos

  • Bayesian network meta-analysis using a treatment sequence model.
  • Key outcomes assessed: clinical response (CDAI-100) and remission (CDAI < 150).

    • Main Results:

    • Ustekinumab 90 mg q8w demonstrated statistically significant improvement in clinical response versus placebo and vedolizumab.
    • Ustekinumab 90 mg q8w also showed statistically significant improvement in clinical remission versus placebo and vedolizumab.
    • Sub-population analyses yielded similar trends, though not statistically significant.

    Conclusions:

    • Ustekinumab appears to offer the highest likelihood of achieving response or remission at one year among the studied biologics.
    • The novel treatment sequence analysis provides a robust method for estimating comparative efficacy in the absence of direct head-to-head trials.
    • Findings suggest ustekinumab as a potentially superior option for long-term Crohn's disease management.